The global radiation therapy market size is calculated at USD 7.86 billion in 2025 and is expected to reach around USD 12.93 ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it has garnered the "Cancer Immunology Solution of the Year" award in the fourth annual ...

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...

Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...